Monday, 16 June 2025 | 10:30 - 12:30
1.2 Parallel session: Optimising the implementation of malaria prevention and treatment strategies
Presentations:
OA-570 - Effect of intermittent preventive treatment in school-age children on malaria incidence in above fifteen years old population in rural Burkina Faso
Serge Henri Zango, Clinical Research Unit of Nanoro/Research Institute for Health Sciences/ National Center for Scientific and Technological Research (URCN/IRSS/CNRST), Burkina Faso
OA-418 - Acceptability and feasibility of implementing perennial malaria chemoprevention integrated into EPI in Togo: lessons learned from the MULTIPLY project
Rodion Konu, Faculty of Health Sciences, Department of Public Health, University of Lomé, Center for Training and Research in Public Health, Togo
OA-429 - Cost-effectiveness of perennial malaria chemoprevention in children under two years of age delivered alongside the expanded program on immunization in Sierra Leone, Togo and Mozambique
Maria Martínez Domínguez, Barcelona Institute of Global Health (ISGlobal), Spain
OA-434 - Effects of dihydroartemisinin-piperaquine for malaria preventive treatment on antiretroviral drugs concentrations and associated factors in African pregnant women living with HIV
Linda Stöger, Barcelona Institute for Global Health (ISGlobal), Spain
OA-384 - Acceptability of dihydroartemisinin-piperaquine as malaria intermittent preventive treatment for pregnant women living with HIV in Southern Mozambique
Tacilta Nhampossa, Manhiça Health Research Center (CISM) - Manhiça Foundation (FM), Mozambique
OA-709 - Strengthening health systems through implementation support strategies: evidence from Kapolowe District, DRC
Tafadzwa Maseko, University of Antwerp, Belgium